PRELUDE: A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Grants and Contracts Details

StatusFinished
Effective start/end date4/1/073/31/10

Funding

  • Eli Lilly and Company: $55,336.00